Please login to the form below

Not currently logged in
Email:
Password:

oxycodone

This page shows the latest oxycodone news and features for those working in and with pharma, biotech and healthcare.

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

Verdict closely follows rejection of Nektar’s opioid analgesic. The FDA’s Anesthetic and Analgesic Committee has rejected yet another opioid drug – this time Intellipharmaceutics’ extended-release oxycodone tablet Aximiris. . ... Aximris was

Latest news

More from news
Approximately 2 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • The transatlantic opioid crisis The transatlantic opioid crisis

    A landmark ruling by a judge in Oklahoma, USA awarded the state record damages of $572m (£468m) from Johnson &Johnson (J&J), the manufacturer of synthetic opioids like oxycodone and fentanyl

  • Pharma deals during November 2013 Pharma deals during November 2013

    The licence is for tamper resistant oxycodone (marketed in the US since 2010) and an oxycodone/naloxone combination marketed in Europe since 2009.

  • Pharma deals during October 2012 Pharma deals during October 2012

    34. ††QRxPharma / Paladin Labs. Licence. MoxDuo IR, fixed dose morphine and oxycodone for pain (NDA filed).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....